Ethnicity and Vasomotor Symptoms in Postmenopausal Women

Appling, Susan; Paez, Kathryn; Allen, Jerilyn K.

doi:10.1089/jwh.2006.0033

Cited by 47 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Likely reasons for the large variability include differences in the demographic characteristics of patient populations, cultural differences in the reporting of adverse events and differences in data collection. 21,22 In our study, incidence rates fall in the middle of the range seen with GnRH agonists, and was comparable whether collected by a non-leading question or the electronic hot flush diary.…”

Section: Discussionsupporting

confidence: 55%

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide

Iversen

Karup

Meulen

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial. In total, 610 prostate cancer patients received monthly degarelix (s.c., 240/80 mg, n ¼ 207, or 240/160 mg, n ¼ 202) or leuprolide (i.m., 7.5 mg, n ¼ 201) for 12 months. Data on hot flushes was collected as self-reported adverse events and in a subgroup of 254 patients with electronic diaries. The onset of hot flushes was faster on degarelix versus leuprolide, and was accompanied by higher median hot flush scores during the first 3 months. However, there were no significant differences in overall incidence rates and median hot flush scores over the entire 12 months. After the third month, incidence rates dropped below 6%, whereas prevalence rates remained constant in all the three treatment arms. In multivariate analysis, body weight and heart rate at baseline were independent predictors of hot flushes (Po0.05). Except for a more rapid onset with the GnRH antagonist, there were no major differences in the overall pattern of hot flushes between treatment options. Weight control may help to minimize the incidence of hot flushes.

show abstract

Section: Discussionsupporting

confidence: 55%

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide

Iversen

Karup

Meulen

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…The high prevalence of obesity among African American women also might be expected to contribute to higher symptom scores in various domains, including hot flushes, muscle and joint problems, physical exhaustion, depressive mood, and bladder problems. 21,22 In addition, previous reports on the attitudes and perceptions of African American women regarding the possible negative effects of hysterectomy on relationships and sexuality 13,14 would suggest that psychologic symptoms, such as anxiety or depression, might be more prevalent among African American women about to undergo hysterectomy. Our data did not support any of these expectations, as there were no significant differences between African American and white women for the total symptom score or for individual domains.…”

Section: Discussionmentioning

confidence: 99%

Reported Symptoms Before and One Year After Hysterectomy in African American and White Women

Moorman

Schildkraut

Myers

et al. 2011

Journal of Women's Health

View full text Add to dashboard Cite

Purpose: Although African American women are more likely than white women to undergo hysterectomy, there are few data describing their symptoms before and after surgery. This report compares reported symptoms in white and African American women before and 1-year after having a hysterectomy with at least one ovary retained. Methods: Using data from a prospective cohort study, we compared self-reported symptoms at baseline and 1-year follow-up among 382 women undergoing hysterectomy without bilateral oophorectomy (197 African American and 185 white) and 448 controls (199 African American and 249 white). Symptoms were assessed using an 11-item scale with questions on somatic, psychologic, and urogenital symptoms. Results: Women undergoing hysterectomy had more severe symptom scores before surgery than controls, but no significant racial differences were found. At follow-up, total scores for women with hysterectomies were comparable to those of control women, but some differences were observed within individual domains. Urogenital scores were worse for women with hysterectomies for both African American and white women. African American women with hysterectomies had better scores in the psychologic domain than either controls or white women with hysterectomies. Conclusions: African American women, despite having such characteristics as larger uterine weight and lower hemoglobin that might suggest they would have more severe symptoms, had scores that were no worse than white women both before and after hysterectomy.

show abstract

“…There are no well established models to account for likelihood of experiencing hot flashes so a base model was created utilizing known risk factors including: (1) use of breast cancer hormone therapy (i.e. tamoxifen or aromatase inhibitors) [3][4][5], (2) use of hormone replacement therapy (HRT) [11], (3) use of selective serotonin reuptake inhibitors (SSRIs) or clonidine [7][8][9] (4) race [28], and (5) menopausal status [29]. The definition of postmenopausal was ''having no menstrual periods for at least 12 months'' or ''history of removal of both ovaries''.…”

Section: Non-genetic Risk Assessmentmentioning

confidence: 99%

Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes

Schneider

Radovich

Flockhart

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Ethnicity and Vasomotor Symptoms in Postmenopausal Women

Cited by 47 publications

References 40 publications

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide

Reported Symptoms Before and One Year After Hysterectomy in African American and White Women

Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes

Contact Info

Product

Resources

About